Genisphere Pursues Neurotherapeutics under Collaboration Agreement with Inserm

Tuesday, October 17, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

HATFIELD, Pa., Oct. 17, 2017 /PRNewswire/ -- Genisphere LLC has signed a collaborative research agreement with The

Institut national de la santé et de la recherche médicale (Inserm, The French National Institute of Health & Medical Research) to study targeted nanotherapeutics for neurological disease. Inserm scientists Dr. Pierre Gressens
and Dr. Bobbi Fleiss will explore a variety of therapeutic molecules with the 3DNA® drug delivery platform provided by Genisphere.

The research project aims to understand the mechanisms of brain development under normal and pathological conditions, in order to decrease poor neurological outcomes associated with abnormal development or injury to the developing brain. Neuroprotective and therapeutic strategies will be evaluated by using the 3DNA nanocarrier to deliver various drug molecules, siRNA, microRNA, peptides or proteins to brain cells in vivo

Dr. Bobbi Fleiss explained, "We have tested a variety of strategies for delivery of therapeutics to the brain with limited success, but 3DNA has shown surprising promise and that it can target and penetrate specific cell types in the brain. Further, two unique payloads, a peptide and a microRNA, have both reduced neuroinflammation in our in vivo models of preterm brain injury." Dr. Pierre Gressens commented, "Our goal is to hit multiple points of pathological pathways to treat genetic and environmental disorders of the developing brain."

Bob Getts, Genisphere's Chief Science Officer, said "Targeting the brain is a high priority for Genisphere. Bobbi and Pierre are true experts in the field of perinatal neuroscience. Now that our 4-year relationship has led to this agreement, we predict future work will provide real advances in neurodegenerative indications such as cerebral palsy and multiple sclerosis among others." 

About GenisphereGenisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic-acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead compounds based on 3DNA® nanotechnology. For more information, please visit

For more information contact:Jessica BowersMarketing Communications,

View original content:

SOURCE Genisphere LLC

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store